Rhenman & Partners Asset Management’s Aerie Pharmaceuticals, Inc. AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-562,350
| Closed | -$4.22M | – | 94 |
|
|
2022
Q2 | $4.22M | Sell |
562,350
-26,850
| -5% | -$201K | 0.48% | 56 |
|
|
2022
Q1 | $5.36M | Sell |
589,200
-160,800
| -21% | -$1.46M | 0.53% | 58 |
|
|
2021
Q4 | $5.38M | Hold |
750,000
| – | – | 0.36% | 68 |
|
|
2021
Q3 | $8.55M | Hold |
750,000
| – | – | 0.6% | 52 |
|
|
2021
Q2 | $12M | Hold |
750,000
| – | – | 0.82% | 51 |
|
|
2021
Q1 | $13.4M | Sell |
750,000
-100,000
| -12% | -$1.79M | 0.93% | 44 |
|
|
2020
Q4 | $11.5M | Hold |
850,000
| – | – | 0.94% | 45 |
|
|
2020
Q3 | $10M | Buy |
850,000
+260,000
| +44% | +$3.06M | 0.89% | 44 |
|
|
2020
Q2 | $8.71M | Sell |
590,000
-130,000
| -18% | -$1.92M | 0.94% | 43 |
|
|
2020
Q1 | $9.72M | Buy |
720,000
+20,000
| +3% | +$270K | 1.36% | 32 |
|
|
2019
Q4 | $16.9M | Buy |
700,000
+225,000
| +47% | +$5.44M | 1.85% | 16 |
|
|
2019
Q3 | $9.13M | Buy |
475,000
+215,000
| +83% | +$4.13M | 1.14% | 36 |
|
|
2019
Q2 | $7.68M | Hold |
260,000
| – | – | 0.85% | 48 |
|
|
2019
Q1 | $12.4M | Sell |
260,000
-20,000
| -7% | -$950K | 1.44% | 26 |
|
|
2018
Q4 | $10.1M | Buy |
280,000
+100,000
| +56% | +$3.61M | 1.16% | 41 |
|
|
2018
Q3 | $11.1M | Buy |
180,000
+110,000
| +157% | +$6.77M | 1.11% | 43 |
|
|
2018
Q2 | $4.73M | Buy |
70,000
+30,000
| +75% | +$2.03M | 0.48% | 62 |
|
|
2018
Q1 | $2.17M | Sell |
40,000
-86,829
| -68% | -$4.71M | 0.27% | 66 |
|
|
2017
Q4 | $7.58M | Buy |
126,829
+5,897
| +5% | +$352K | 1.02% | 38 |
|
|
2017
Q3 | $5.88M | Buy |
120,932
+45,932
| +61% | +$2.23M | 0.75% | 52 |
|
|
2017
Q2 | $3.94M | Sell |
75,000
-10,000
| -12% | -$525K | 0.57% | 63 |
|
|
2017
Q1 | $3.86M | Buy |
85,000
+50,000
| +143% | +$2.27M | 0.61% | 59 |
|
|
2016
Q4 | $1.33M | Buy |
+35,000
| New | +$1.33M | 0.25% | 80 |
|